Standard of Care sensibility: Rituximab = yes
Granta cells
Human Granta cells were isolated from the pleural effusion of a patient with non-hogkin’s mantle cells lymphoma.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing Granta tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the Granta cells as xenograft
Mean ± SEM (n=8; take rate 87.5%)
Antineo can also perform an intra-medullar implantation.
Standard-Of-Care Drug Responses
rituximab 30 mg/kg qw → Response
Figure 2: (View PDF)
Effect of rituximab treatment on Granta tumour growth
Mean ± SEM (n=3 per group; take rate 100%)
A Granta resistant to rituximab model, developed in vivo without genetic modifications, are available at Antineo (model ID Granta rituxR).